Table of Contents
Conference Papers in Medicine
Volume 2013, Article ID 386913, 2 pages
http://dx.doi.org/10.1155/2013/386913
Conference Paper

Report of the Pilot Study Done for the Proposed Investigation on the Possible Synergic Effect between High-Dose Ascorbic Acid Application and Oncothermia Treatment

1Pharmacology and Toxicology Department, Faculty of Veterinary Science, Szent Istvan University, Budapest 1078, Hungary
21st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest 1085, Hungary
3University of Tottori, Tottori 680-8550, Japan
4Biotechnics Department, Faculty of Mechanical Engineering, Szent Istvan University, Gödöllő 2100, Hungary

Received 15 January 2013; Accepted 17 April 2013

Academic Editors: G. F. Baronzio, M. Jackson, and A. Szasz

This Conference Paper is based on a presentation given by Csaba Kovago at “Conference of the International Clinical Hyperthermia Society 2012” held from 12 October 2012 to 14 October 2012 in Budapest, Hungary.

Copyright © 2013 Csaba Kovago et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Cameron and L. Pauling, “Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 9, pp. 4538–4542, 1978. View at Google Scholar · View at Scopus
  2. E. T. Creagan, C. G. Moertel, and J. R. O'Fallon, “Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial,” The New England Journal of Medicine, vol. 301, no. 13, pp. 687–690, 1979. View at Google Scholar · View at Scopus
  3. M. Levine, M. G. Espey, and Q. Chen, “Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment,” Free Radical Biology and Medicine, vol. 47, no. 1, pp. 27–29, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. Q. Chen, J.-H. Lee, L. Zhang et al., “Pharmacologic ascorbate concentrations selectively kill cancer cells: ascorbic acid as a prodrug for ascorbate radical or H2O2 delivery to tissues,” The Journal of Nutrition, vol. 137, no. 1, p. 293s, 2007. View at Google Scholar
  5. S. J. Padayatty, H. Sun, Y. Wang et al., “Vitamin C pharmacokinetics: implications for oral and intravenous use,” Annals of Internal Medicine, vol. 140, no. 7, pp. 533–I61, 2004. View at Google Scholar · View at Scopus
  6. L. J. Hoffer, M. Levine, S. Assouline et al., “Phase I clinical trial of i.v. ascorbic acid in advanced malignancy,” Annals of Oncology, vol. 19, no. 11, pp. 1969–1974, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Du, J. J. Cullen, and G. R. Buettner, “Ascorbic acid: chemistry, biology and the treatment of cancer,” Biochimica et Biophysica Acta, vol. 1826, no. 2, pp. 443–457, 2012. View at Publisher · View at Google Scholar